SFA Therapeutics

SFA Therapeutics is dedicated to developing innovative, orally administered therapeutics that modulate the immune system. The company's primary focus is on addressing autoimmune diseases and cancers stemming from chronic inflammation, a condition affecting over 300 million individuals globally. Their therapeutic approach targets the underlying causes of many chronic inflammatory diseases through safe, orally available medications. SFA Therapeutics has demonstrated promising clinical results from a Phase 1b clinical trial in psoriasis, as well as human data in pancreatic cancer, uveitis, and NASH. The company boasts a robust pipeline of nine drug candidates and a strong intellectual property portfolio with 15 patents.